Taiho Oncology

Taiho Oncology has a pipeline in oral oncology, including novel antimetabolites and selective targeted agents. The anticancer drug LONSURF (trifluridine and tipiracil) was approved by the FDA in September 2015 and launched in the U.S. market by Taiho Oncology in October 2015. Established in 2002 in New Jersey, U.S., as a subsidiary of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd. Taiho Oncology is a different kind of pharmaceutical company. With deep roots and unparalleled corporate agility, Taiho Oncology is able to achieve its mission – creating a better world for cancer patients and those who care for them. The corporate philosophy of Taiho Oncology is "We strive to improve human health and contribute to a society full of smiles."